GLAXOPharmaceuticals
GlaxoSmithKline Pharmaceuticals Ltd — Cash Flow Statement
₹2283.00
-3.43%
GlaxoSmithKline Pharmaceuticals Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | 1.27K Cr | 550.79 Cr | 440.19 Cr | 776.11 Cr | — |
| Capital Expenditure | -24.72 Cr | -31.22 Cr | -44.04 Cr | -34.64 Cr | — |
| End Cash Position | 538.85 Cr | 64.17 Cr | 34.94 Cr | 286.19 Cr | — |
| Beginning Cash Position | 64.17 Cr | 34.94 Cr | 286.19 Cr | 405.19 Cr | — |
| Changes In Cash | 474.68 Cr | 29.23 Cr | -251.25 Cr | -119.00 Cr | — |
| Financing Cash Flow | -769.42 Cr | -561.50 Cr | -1.54K Cr | -524.24 Cr | — |
| Interest Paid Cff | -1.31 Cr | -1.80 Cr | -1.40 Cr | -1.99 Cr | — |
| Cash Dividends Paid | -749.38 Cr | -541.57 Cr | -1.53K Cr | -506.63 Cr | — |
| Common Stock Dividend Paid | -749.38 Cr | -541.57 Cr | -1.53K Cr | -506.63 Cr | — |
| Investing Cash Flow | -45.80 Cr | 8.71 Cr | 807.85 Cr | -405.51 Cr | — |
| Net Other Investing Changes | -0.66 Cr | -2.28 Cr | -298.61 Cr | 1.55K Cr | — |
| Interest Received Cfi | 118.29 Cr | 93.43 Cr | 62.97 Cr | 43.96 Cr | — |
| Net Investment Purchase And Sale | -144.43 Cr | -145.38 Cr | 956.29 Cr | -1.81K Cr | — |
| Sale Of Investment | 5.30K Cr | 5.66K Cr | 6.22K Cr | 1.26K Cr | — |
| Purchase Of Investment | -5.44K Cr | -5.80K Cr | -5.26K Cr | -3.07K Cr | — |
| Net PPE Purchase And Sale | -19.00 Cr | -7.07 Cr | -42.58 Cr | -33.46 Cr | — |
| Sale Of PPE | 5.72 Cr | 24.16 Cr | 1.46 Cr | 1.18 Cr | — |
| Purchase Of PPE | -24.72 Cr | -31.22 Cr | -44.04 Cr | -34.64 Cr | — |
| Operating Cash Flow | 1.29K Cr | 582.02 Cr | 484.23 Cr | 810.75 Cr | — |
| Taxes Refund Paid | -81.71 Cr | -230.38 Cr | -262.42 Cr | -112.23 Cr | — |
| Change In Working Capital | 184.83 Cr | 61.02 Cr | -45.75 Cr | 119.87 Cr | — |
| Change In Other Current Liabilities | 57.34 Cr | 15.21 Cr | -25.28 Cr | -59.76 Cr | — |
| Change In Other Current Assets | 59.09 Cr | -11.80 Cr | -43.81 Cr | -16.23 Cr | — |
| Change In Payable | 76.97 Cr | 190.14 Cr | -153.22 Cr | 102.37 Cr | — |
| Change In Inventory | 43.31 Cr | -65.08 Cr | 74.72 Cr | 12.00 Cr | — |
| Change In Receivables | -72.87 Cr | -30.27 Cr | 20.23 Cr | 10.20 Cr | — |
| Other Non Cash Items | -69.44 Cr | -65.73 Cr | -67.60 Cr | -1.70K Cr | — |
| Provisionand Write Offof Assets | 2.38 Cr | 0.59 Cr | -7.36 Cr | 0.15 Cr | — |
| Depreciation And Amortization | 66.79 Cr | 69.68 Cr | 65.77 Cr | 68.19 Cr | — |
| Amortization Cash Flow | 10.22 Cr | 10.54 Cr | 9.69 Cr | 9.47 Cr | — |
| Depreciation | 56.57 Cr | 59.14 Cr | 65.77 Cr | 58.72 Cr | — |
| Gain Loss On Investment Securities | -69.65 Cr | -48.78 Cr | -30.78 Cr | -0.59 Cr | — |
| Gain Loss On Sale Of PPE | 1.51 Cr | -0.89 Cr | -0.03 Cr | -0.32 Cr | — |
| Net Income From Continuing Operations | 1.26K Cr | 959.80 Cr | 841.49 Cr | 2.48K Cr | — |
| Net Investment Properties Purchase And Sale | — | 19.69 Cr | 9.78 Cr | 32.34 Cr | 1.84 Cr |
| Sale Of Investment Properties | — | 19.69 Cr | 9.78 Cr | 32.34 Cr | 1.84 Cr |
| Repayment Of Debt | — | — | 0.00 | -0.02 Cr | -0.15 Cr |
| Net Other Financing Charges | — | — | 0.44 Cr | — | — |
| Net Issuance Payments Of Debt | — | — | 0.00 | -0.02 Cr | -0.15 Cr |
| Net Long Term Debt Issuance | — | — | 0.00 | -0.02 Cr | -0.15 Cr |
| Long Term Debt Payments | — | — | 0.00 | -0.02 Cr | -0.15 Cr |
| Net Business Purchase And Sale | — | — | — | 0.00 | 180.00 Cr |
| Sale Of Business | — | — | — | 0.00 | 180.00 Cr |
| Deferred Tax | — | — | — | 8.28 Cr | 93000.00 |
| Capital Expenditure Reported | — | — | — | — | -44.23 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on GlaxoSmithKline Pharmaceuticals Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.